Atea Pharmaceuticals, Inc. (AVIR)

Market Cap	266.90M
Revenue (ttm)	n/a
Net Income (ttm)	-174.01M
Shares Out	84.46M
EPS (ttm)	-2.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	167,552
Open	3.120
Previous Close	3.140
Day's Range	3.095 - 3.160
52-Week Range	2.765 - 4.600
Beta	0.17
Analysts	Hold
Price Target	6.88 (+117.72%)
Earnings Date	Nov 7, 2024

About AVIR

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 30, 2020
• Employees: 75
• Stock Exchange: NASDAQ
• Ticker Symbol: AVIR
• Website: https://ateapharma.com

Analyst Forecast

According to one analyst, the rating for AVIR stock is "Hold" and the 12-month stock price forecast is $6.88.

Price Target

$6.88

(117.72% upside)

Analyst Consensus: Hold